Vida Health Expands Its Cardiometabolic Capabilities To Include GLP-1s for Diabetes Management & Weight Loss

Vida Health is expanding its solution for chronic conditions by adding the ability to prescribe and deprescribe glucagon-like peptide 1 (GLP-1) agonists for both type 2 diabetes and obesity for appropriate consumers. As part of Vida’s value-oriented treatments for cardiometabolic conditions, consumers with obesity and diabetes will now be candidates for GLP-1 therapy within the Vida platform.

With the addition of GLP-1s and other obesity medications in higher acuity cases, Vida Health will be able to provide patients with obesity and type 2 diabetes a more comprehensive and integrated set of options for managing . . .